Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseasesNathan A. Berger, Csaba Szabó, Alberto Chiarugi et al.|British Journal of Pharmacology|2017Cited by 210
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft linesMichelle J. Clarke, Jann N. Sarkaria, Evan A. Mulligan et al.|Molecular Cancer Therapeutics|2009Cited by 94
mTORC1 and DNA‐PKcs as novel molecular determinants of sensitivity to Chk1 inhibitionAndrew J. Massey, Nicola J. Curtin|Molecular Oncology|2015Cited by 24
Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and SchedulingHannah L. Smith, Nicola J. Curtin|Cancers|2022Cited by 8